Memorial Sloan Kettering Cancer Center is recruiting patients for a PHASE2 clinical trial testing immunotherapy for mesothelioma.
The trial, designated NCT06477419, aims to enroll up to 33 participants at 7 sites, including locations in New Jersey, New York.
About the Study
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it’s in your best interest to stop treatment.
Treatment Approach
This trial uses checkpoint inhibitor immunotherapy.
Key trial details:
- Phase: PHASE2
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrollment target: 33
- Status: RECRUITING
Why This Trial Matters
Memorial Sloan Kettering is one of the leading mesothelioma treatment centers in the United States.
Study Locations
The trial is recruiting at:
- Memorial Sloan Kettering Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth, New Jersey
- Memorial Sloan Kettering Bergen, New Jersey
- Memorial Sloan Kettering Cancer Center @ Commack, New York
- Memorial Sloan Kettering Westchester, New York
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening